Logan Lutton

In a Q&A with Leanne Berge, J.D., CEO of Community Health Plan of Washington, Berge explains what the newly proposed Medicaid bill would mean for enrollees and healthcare systems if passed.

Homelessness and HIV share common risk factors, according to Julie Dombrowski, M.D., M.P.H., professor of medicine at the University of Washington and director of HIV treatment initiatives at the King County, Seattle public health department.

Here’s what you missed this week on Managed Healthcare Executive.

While providers do bring up menopause with patients during visits, there are still some knowledge gaps, according to the results of a recent survey of women ages 40 to 70 and healthcare providers.

Previously used to treat HIV and Hepatitis B, nucleoside reverse transcriptase inhibitors (NRTIs) reduced the risk of Alzheimer’s disease by an average of 9% every year, according to new research published in Alzheimer’s and Dementia.

An overview of endometriosis subtypes, treatment options and costs, according to a recent research review published in JAMA.

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

Finding a cure for inflammatory bowel disease (IBD) would mean reducing treatment waste, according to Ashwin N. Ananthakrishnan, M.D., M.P.H., MGH, associate professor of medicine at Massachusetts General Hospital and Johan Burisch, M.D., Ph.D., a gastroenterologist at Hvidovre Hospital in Denmark.

Here’s what you missed this week on Managed Healthcare Executive.

Children and young adults living in states with the biggest drops in Medicaid coverage experienced more prescription disruptions for their chronic conditions than those living in states with smaller drops, according to a new study by researchers at the University of Michigan.

Digital pharmacy solutions can help brick and mortar locations become more efficient, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

A growing and more diverse pipeline means that there is a greater need for digital innovations, which can address affordability, access and industry collaboration, according to Sarah Thomas, VP of sales and commercialization at HealthDyne and David Skomo, COO of HealthDyne.

Becky Davis of Charles River Associates predicts that an influx of new and oral GLP-1 drugs, along with pricing pressures from policy and competition, will reshape the weight loss drug market in the next two years.

The victims of intimate partner violence were found to have more menopause symptoms, according to the results of a Turkish study published this month in Menopause.

At the 2024 Asembia Specialty Pharmacy Summit, Becky Davis, principal at Charles River Associates, discussed how employer-based insurance coverage for GLP-1s remains uneven—and what factors are influencing decisions about access to these weight-loss treatments.

Fran Gregory, PharmD, MBA, VP of emerging therapies at Cardinal Health, talks about the importance of market access strategies in the cell and gene therapy space.

A future where healthcare may include augmented reality, robots and drones may be more fact than fiction, says George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.

As healthcare AI evolves, there will be a greater emphasis on streamlining administrative tasks, drug production and service delivery, according to George Van Antwerp, SVP of product innovation and strategic planning at Prime Therapeutics.

Patients and providers found common ground on the importance of correct billing estimates but did not see eye to eye in terms of digital scheduling tool use, according to a new survey by Experian Health.

There is a lack of agreement on the clinical, psychological and social relevance of menopause between the transgender and gender diverse communities and medical professionals, according to the results of a study published this month in Menopause.

Women who undergo menopause before the age of 40 are more likely to experience cognitive decline, which may lead to dementia, according to new research.

Here’s what you missed this week on Managed Healthcare Executive.

Medicaid is the main healthcare coverage for people living with HIV in the United States, according to data compiled by KFF.

The difference between specialty drugs and traditional drugs and how each have vied for market competition, according to Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics.

In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.

Here’s what you missed this week on Managed Healthcare Executive.

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States.

Current observations and foresight into the world of biosimilars, GLP-1s, PBM and payer trends, according to Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, and Doug Long, MBA, vice president of industry relations at IQVIA.

In United States veterans, antiretroviral resistance was associated with higher healthcare resource utilization, despite lower pharmacy-related costs, according to an abstract submitted to the Academy of Managed Care Pharmacy (AMCP) held last week in Houston.